Creative Biolabs Sheds Light on Vaccine-Based Anti-Monkeypox Drug Discovery

Creative Biolabs remains dedicated to cutting-edge solutions for the monkeypox virus, pushing the boundaries of innovation in new drug development and drug development.
New York, USA - April 21, 2025 - As monkeypox outbreaks continue to challenge global health infrastructure, Creative Biolabs has expanded its state-of-the-art drug discovery capabilities, focusing on three distinct vaccine-based strategies: virus-like particle (VLP) vaccines [https://monkeypox.creative-biolabs.com/virus-like-particle-vaccine-based-anti-monkeypox-drug-discovery-solutions.htm], inactivated virus vaccines [https://monkeypox.creative-biolabs.com/inactivated-virus-vaccine-based-anti-monkeypox-drug-discovery-solutions.htm], and DNA vaccines. Each strategy is engineered to address critical challenges in vaccine development, offering partners distinct strengths in speed and precision.

Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg

Creative Biolabs' VLP platform involves advanced protein engineering to engineer non-replicative particles mimicking the monkeypox virus structure. This eliminates replication risk and provides strong humoral and cellular immunity. Creative Biolabs' patented high-yield expression systems support rapid, cost-effective production, which is the best choice for bulk production.

"We generate VLPs through recombinant techniques in broadly used baculovirus, tobamovirus, geminivirus, or Venezuelan equine encephalitis replicon expression systems," noted a researcher at Creative Biolabs. "Structural characteristics of VLPs are also analyzed by structural techniques and imaging analysis to confirm correct folding of capsid proteins assembling the VLPs."

The company is also dedicated to the development of inactivated virus vaccines and DNA vaccine-based anti-monkeypox drug discovery [https://monkeypox.creative-biolabs.com/dna-vaccine-based-anti-monkeypox-drug-discovery-solutions.htm] using cutting-edge technologies and deep expertise in virus research. Their full-cycle drug discovery services target the stabilization and validation of the efficacy of vaccine candidates, delivering clients tailored one-stop solutions to meet their individual needs. Dedicated to innovation, this firm contributes to accelerating the rapid development of monkeypox drugs.

"Our products are based on innovation and a deep understanding of viral pathogenesis," said a lead scientist at Creative Biolabs. "By bridging traditional approaches with the latest technologies, we help partners advance the development of efficient vaccines with fewer side effects."

Why Select Creative Biolabs?

* End-to-End Experience: Over 20 years of virology, immunology, and preclinical development experience.

* State-of-the-Art Facilities: Equipped facilities for quick prototyping, testing, and large-scale production.

* Personalized Solutions: Personalized solutions for specific project objectives, from antigen design to adjuvant optimization.

Visit https://monkeypox.creative-biolabs.com for more information.

About Creative Biolabs

Creative Biolabs is a world-renowned drug discovery and vaccine development partner, providing end-to-end services ranging from target identification to clinical trial support. Focusing on infectious diseases, the company pairs scientific excellence with operational agility to provide solutions to research challenges.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=creative-biolabs-sheds-light-on-vaccinebased-antimonkeypox-drug-discovery]
Phone: 1-631-830-6441
Country: United States
Website: https://monkeypox.creative-biolabs.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.